Tivozanib (Fotivda®) is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||09/01/2019|
|Rapid review completed||24/01/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tivozanib compared with the current standard of care.|
The HSE has approved reimbursement following confidential price negotiations August 2019.